Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 2c
Tweet
Share
E-mail
Get Alerts CRVS Hot Sheet
Join SI Premium – FREE
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q4 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12).
For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
- Standard Uranium closes first tranche of private placement at $0.10
- Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
